Can GLP-1 drugs treat addiction? A new study hints at their potential

A large BMJ epidemiological study of more than 600,000 U.S. veterans with type 2 diabetes followed for three years found that GLP-1 medications were associated with broad reductions in substance use disorders and related harms: a 14% reduced risk across all substance use conditions among those without prior SUDs (with a 25% drop for opioid use disorders) and, among those with existing SUDs, a 31% reduction in SUD-related ED visits, 26% fewer hospital admissions, 39% fewer overdoses, 25% fewer suicidal ideation/attempts and a 50% reduction in drug-related deaths. The findings—while limited by a largely older white male veteran cohort and lack of dosing/type comparisons—imply a potential large off-label market opportunity and clinical benefit for GLP-1 drug makers if results replicate in broader, randomized trials.

Analysis

Market structure: Incumbent GLP-1 manufacturers (Novo Nordisk NVO, Eli Lilly LLY) are primary beneficiaries — potential new indication set expands addressable market beyond obesity/diabetes to substance-use disorder (SUD) prevention/treatment, implying revenue upside of low-single-digit % of current sales per year if even 5–10% of the diabetic/non-diabetic population are treated over 2–5 years. Payors and large pharmacy suppliers (CVS, Walgreens) gain negotiating leverage; specialty rehab providers and acute-care revenue lines (ER admissions) face modest demand erosion if inpatient SUD events decline ~25–40% as the study suggests.

Risk assessment: Key tail risks include payer coverage reversal, regulatory limits on off-label use, safety litigation, and supply constraints (injectable manufacturing). Time windows: immediate sentiment moves (days–weeks) on headlines; short-term (3–12 months) hinge on RCT readouts and insurer policy changes; long-term (1–3 years) depends on label expansion and production scale. Hidden dependencies: manufacturing capacity, raw-material suppliers, and VA/Medicare coverage rules; a single production bottleneck could lift prices 10–30% temporarily.

Trade implications: Prefer concentrated exposure to scale players (NVO, LLY) via equity + LEAP calls while underweighting small-cap rehab/service providers and certain hospital ER revenue exposures (HCA). Use 12–24 month bullish option structures to capture binary regulatory/clinical catalysts; consider a small long in payors (UNH) to capture claim-cost tailwinds. Size positions conservatively (1–3% per idea) and add on clinical/regulatory confirmations.

Contrarian view: Consensus may underprice regulatory pushback and payer resistance — adoption in non-diabetics could be slower than headlines imply; avoid speculative small-cap GLP-1 entrants and assume only incumbents can scale fast enough. Historical parallels (off-label psychiatric drug booms) show rapid hype followed by payer retrenchment; unintended consequences include diversion, shortages for diabetics, and reputational/legal risk that could compress multiples by >10% on adverse news.

Key Decisions for Investors

• Establish a 3% long position split: 1.5% NVO (Novo Nordisk) and 1.5% LLY (Eli Lilly) as core exposure to GLP-1 upside; hold 12–24 months and add another 0.5–1.0% if an FDA label expansion or strong Phase III SUD RCT is announced within 6–12 months.
• Buy 12–18 month LEAP calls to leverage upside: allocate 0.5% of portfolio to NVO Jan 2027 calls (delta ~0.35–0.5) and 0.5% to LLY Jan 2027 calls; cap loss at premium paid and plan to roll or sell on a 25–40% premium move or on negative regulator news.
• Initiate a 1% long position in UNH (UnitedHealth) to capture potential claim-cost tailwinds from reduced SUD admissions over 1–3 years; trim by 50% if payor guidance indicates no material claims improvement within 12 months.
• Establish a 1% net short/underweight in small-cap addiction-treatment and rehab operators (example tactical short ACAD 0.5% and underweight HCA 0.5%)—expect 6–18 month pressure as outpatient management and fewer ER visits reduce acute care revenue; cover if GLP-1 access is materially restricted by insurers for >6 months.
• Monitor three catalysts over the next 90 days and act: (1) RCTs or multisite trial starts (add 0.5–1% to longs on positive results), (2) major payer coverage decisions (reduce longs if widespread denial occurs), (3) manufacturing capacity reports from NVO/LLY (buy-on-bottleneck-driven price jumps >15%).